for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion
Principal Investigator
by Teresa De Marco, MD
Photo of Teresa De Marco
Teresa De Marco



The objectives of the RELIEVE-PAH study are to obtain first-in-human experience with the study device in patients with severe pulmonary arterial hypertension, including evidence of initial safety, device performance and possible signals of clinical effectiveness.

Official Title

RELIEVE-PAH TRIAL: REducing Right ventricuLar faIlure With thE V-waVe Shunt in Pulmonary Arterial Hypertension


This is a multi-national, multi-center, prospective, non-randomized, open label trial of patients implanted with the study device. A total of 20 patients will be implanted with the study device and followed at regular intervals for 1 year and then annually for a total of 5 years post implant.


Pulmonary Arterial Hypertension PAH Interatrial Shunt Interatrial Shunting Atrial Septostomy Familial Primary Pulmonary Hypertension Hypertension V-Wave Interatrial Shunt Therapy: V-Wave Shunt


You can join if…

Open to people ages 18 years and up

  1. Group 1 PAH (idiopathic, connective tissue disease, HIV, corrected congenital heart disease).
  2. World Health Organization Functional Class III or IV symptoms or history of syncope.
  3. Receiving maximal available and tolerable pharmacological PAH therapy at stable dose for ≥4 months.

You CAN'T join if...

  1. Resting oxygen saturation <90 % without supplemental oxygen corrected for altitude.
  2. Mean Right Atrial Pressure >20 mmHg.
  3. Severe restrictive or obstructive lung disease.
  4. Evidence of organ dysfunction other than right heart failure.
  5. Left ventricular ejection fraction <40 %.
  6. Anatomical anomaly on transesophageal echocardiography or intracardiac echocardiography that precludes implantation of Shunt across fossa ovalis (FO) of the interatrial septum.
  7. Inadequate vascular access for implantation of shunt, e.g. femoral venous access for transseptal catheterization and inferior vena cava (IVC) is not patent.
  8. Hemodynamic heart rhythm, or respiratory instability at time of Final Exclusion Criteria.


  • University of California, San Francisco accepting new patients
    San Francisco California 94143 United States
  • Keck Medical Center of USC accepting new patients
    Los Angeles California 90033 United States

Lead Scientist at UCSF

  • Teresa De Marco, MD
    CLINICAL INTERESTS: Advanced heart failure, cardiomyopathies, heart transplantation, mechanical circulatory support, and pulmonary hypertension RESEARCH INTERESTS: Translational research in the diagnosis, prognosis, medical and surgical treatment for the above disease states


accepting new patients
Start Date
Completion Date
V-Wave Ltd
Study Type
Last Updated